AID beyond glucose metrics
What this study tests
Randomized study of switching to automated insulin delivery versus usual care in adults and children with T1D. The primary outcome is sleep efficiency measured over three nights at baseline and week 18, rather than glucose control alone.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2024-06-21.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults with T1D for at least 3 years or children 7–17 with T1D for at least 6 months; CGM use for at least 6 months and clinician approval to start AID are required. Previous commercial or open-source AID use is excluded. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted yet.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: European Union. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Difference in change from baseline to study end in sleep efficiency between the two groups.
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]NCT06469593: AID beyond glucose metrics · Trial registry